Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia 10Burkitt Lymphoma 9Recurrence 8Lymphoproliferative Disorders 6Lymphoma, Non-Hodgkin 5Lymphatic Diseases 5Immunoproliferative Disorders 4Neoplasms 3Neoplasm, Residual 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Lymphoid 2Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Large Granular Lymphocytic 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Bites and Stings 1

Interventions

Whole-Body Irradiation 14Mycophenolic Acid 14fludarabine phosphate 13Cyclophosphamide 13Cytarabine 11Methotrexate 9Granulocyte Colony-Stimulating Factor 9Filgrastim 9Cyclosporine 8Peripheral Blood Stem Cell Transplantation 7Vincristine 6Thiotepa 6Tacrolimus 6Dexamethasone 6Cord Blood Stem Cell Transplantation 6merphos 5fludarabine 5Mitoxantrone 5Clofarabine 5Calcium Dobesilate 5Busulfan 5Mercaptopurine 4Melphalan 4Leucovorin 4Cladribine 4pegaspargase 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Biphenotypic, Acute × blinatumomab × Clear all
NCT02879695 2026-05-29

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1 Active not recruiting
28 enrolled 16 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡